Regeneron Pharmaceuticals holds the cleaner structural position, with valuation as the main driver and growth adding further support. Edwards Lifesciences still has the edge on growth, which keeps the comparison from looking entirely one-sided. The market setup is currently leaning toward Edwards Lifesciences, which does not confirm the structural lead. That leaves a split case: the structural lead stays with Regeneron Pharmaceuticals, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the S&P 500 universe, making them directly comparable.
This is not just a one-metric split: both valuation and stability materially support the lead. Regeneron Pharmaceuticals, Inc. leads by 12 points on the overall comparison score.
These two companies are linked by measured long-term financial trajectory similarity within the selected peer universe.
A moderate similarity means the pair is structurally comparable, but not a near-twin trajectory match.
Most of the shared profile comes through operating margin level and revenue stability.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
Score differences across key dimensions.
Left means cheaper relative valuation. Higher means stronger structure.
Structure stays fairly close here, while current pricing still looks more supportive for Regeneron Pharmaceuticals, Inc..
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where EW and REGN each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The multiple-based pricing edge comes from a forward P/E that is 15.9 turns lower.
Growth still tilts materially toward Edwards Lifesciences Corporation, which stops the result from looking dominant across the whole profile.
The valuation lead is clear, but pricing and growth still pull in the other direction — the result holds, but not without friction.
Break down the EW vs REGN comparison across all dimensions with the full interactive tool.
Explore how EW and REGN each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.